ICER and cost control guru Peter Bach are slamming the brakes on innovation

No matter what side of the aisle you’re on, we can all agree that medical progress should be celebrated and accelerated, not halted or even slowed.

New Yorkers know this. The Big Apple is the beating heart of the research that leads to such progress. Mount Sinai, Presbyterian, St. Jude’s, NYU Langone, Memorial Sloan Kettering Cancer Center – the city’s hospitals and medical research facilities are leading the charge to treat and cure the diseases that afflict millions. Miracles are happening here.

But all is not well. The city also hosts one of the most prominent advocates for price controls on medical innovations: Peter Bach, the director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes.

Continue reading at

About the Author
Jonathan Wilcox is a leading public policy expert who served in the California Governor’s Office and a Professor of Public Relations at the USC Annenberg School for Communication. He is policy director at Patients Rising, a non-profit organization that advocates for patients with life-threatening diseases.